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Abstract
Background
Protein glycosylation is an important post-translational modification shown to be altered in
all tumour types studied to date. Mucin glycoproteins have been established as important
carriers ofO-linked glycans but other glycoproteins exhibiting altered glycosylation reper-
toires have yet to be identified but offer potential as biomarkers for metastatic cancer.
Methodology
In this study a glycoproteomic approach was used to identify glycoproteins exhibiting alter-
ations in glycosylation in colorectal cancer and to evaluate the changes in O-linked glyco-
sylation in the context of the p53 and KRAS (codon 12/13) mutation status. Affinity
purification with the carbohydrate binding protein from Helix pomatia agglutinin (HPA) was
coupled to 2-dimensional gel electrophoresis with mass spectrometry to enable the identifi-
cation of low abundance O-linked glycoproteins from human colorectal cancer specimens.
Results
AberrantO-linked glycosylation was observed to be an early event that occurred irrespec-
tive of the p53 and KRAS status and correlating with metastatic colorectal cancer. Affinity
purification using the lectin HPA followed by proteomic analysis revealed annexin 4,
annexin 5 and CLCA1 to be increased in the metastatic colorectal cancer specimens. The
results were validated using a further independent set of specimens and this showed a sig-
nificant association between the staining score for annexin 4 and HPA and the time to
metastasis; independently (annexin A4: Chi square 11.45, P = 0.0007; HPA: Chi square
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9.065, P = 0.0026) and in combination (annexin 4 and HPA combined: Chi square 13.47;
P = 0.0002).
Conclusion
Glycoproteins showing changes inO-linked glycosylation in metastatic colorectal cancer
have been identified. The glycosylation changes were independent of p53 and KRAS sta-
tus. These proteins offer potential for further exploration as biomarkers and potential targets
for metastatic colorectal cancer.
Background
Glycosylation is an important post translational modification that has been shown to be altered
in all cancer types studied to date. The genes coding for enzymes involved in glycosylation
reactions account for approximately 1% of the human genome explaining the myriad of glyco-
sylation changes reported in cancer. Metastasis, the dissemination of cells from the primary
tumour to distant organs, is a major problem affecting patients diagnosed with colorectal can-
cer (CRC) [1]. Accordingly, early diagnosis of metastatic CRC is an important aim and new
prognostic markers are needed to identify patients at the highest risk of developing metastases
to enable oncologists to tailor treatment strategies to high risk groups of patients.Alterations in
glycosylation have been shown to be associated with the metastatic behaviour of tumour cells
[2,3] and may be identified using carbohydrate binding proteins, lectins, isolated from a wide
variety of organisms including bacteria, plants, invertebrates and vertebrates [4]. The lectin
Helix pomatia agglutinin (HPA) recognises O-linked glycan structures [5,6] and was first
shown to bind preferentially to breast cancer from patients with poor prognosis [2] [7]. The
utility of HPA for detecting metastatic cancer has since been shown for a range of solid
tumours including those of the gastrointestinal tract, for example, colorectal, gastric and oeso-
phageal tumours [8–11]. The glycoproteins recognized by HPA have been investigated in CRC
derived cell lines and this revealed that the utility of HPA lies in its ability to simultaneously
bind to many glycoproteins involved in a range of pro-metastatic functions including cell
migration, anti-apoptosis and cell signalling [12]. HPA has been shown to bind the same glyco-
proteins in breast cancer as those detected in HT29 cells suggestive that HPA recognises
changes in glycosylation that are common across solid tumour types. HPA recognises glyco-
proteins modified by the attachment of O-linked N-acetylgalactosamine (O-GalNAc) and N-
acetylglucosamine (O-GlcNAc) [13]. Cancer associated changes in O-linked glycosylation have
been recognised for some time but there have been relatively few studies concerned with map-
ping the proteins to which the altered glycans are attached.In the current study, the lectin HPA
was used to identify O-linked glycoproteins of CRC tissues that were metastatic to the lymph
nodes. Proteins were pre-enriched by lectin affinity chromatography and separated by two–
dimensional gel electrophoresis (2-DE) followed by identification using mass spectrometry
(MS). Verification of the glycoproteins identified was performed by immunohistochemistry
andWestern blotting. The correlation between HPA binding; mutated P53 in KRAS and the
CEA status of the tissue samples was evaluated with the aim of understanding O-linked glyco-
sylation in the context of other markers for CRC. A validation study with a further collection of
CRC specimens independent of the initial sample cohort showed that the changes in O-linked
glycosylation recognised by HPA remain associated with poor prognosis CRC.
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Materials and Methods
Chemicals were obtained from Sigma-Aldrich, Poole, Dorset, UK, unless otherwise stated.
Patient samples
The proteomic study included 27 patients with primary CRC, known to be free of liver metas-
tases, all of whom underwent surgical resection at the University Hospital, Martinique (S1
Table). The study was approved by the Ethics Committee of the Medical School of Martinique
and the University Research Ethics Committee (UREC) of the University of Westminster. All
patients gave written informed consent for their samples to be used in research. Samples were
snap-frozen after surgery and equivalent samples were fixed in formaldehyde and embedded in
paraffin for histopathological studies. For each cancer tissue sample, normal tissue was col-
lected from tumour free areas in the neighbouring mucosa within a radius of 4 cm of the
tumour. Patients were categorised into two groups based on the degree of the involvement of
the regional lymph nodes. All the tissues used in the investigation were examined and verified
for the presence of tumour cells using haematoxylin and eosin-stained slides. The validation
work was performed using paraffin-was embedded blocks of CRC tissue collected at University
College London Hospitals (prior to 2006) and used in accordance with the Human Tissue Act
(2008).
Histochemistry
The immunohistochemistry used the horseradish-peroxidase (HRP) detection system (EnVi-
sion kit plus Dual link system-HRP complex, Anti-Mouse/Rabbit-HRP, Dako, Carpinteria,
CA, USA) according to the manufacturer's instructions. Briefly, 4 μm thick sections from the
formalin-fixed paraffin-wax embedded (FFPE) archival colon tissues (tumours and normal
counterparts) were de-paraffinized in xylene and rehydrated through a series of graded alco-
hols (70% - 100%). Antigen retrieval was performed using the Target Retrieval Solution or cit-
rate buffer following manufacturer’s instructions. Endogenous peroxidase activity was
quenched by incubation with the Dual Endogenous Enzyme block (Dako, Carpinteria, CA,
USA). Sections were incubated with the respective primary antibody: monoclonal anti-p53
(clone DO1; Immunotech, dilution 1:50) or rabbit polyclonal antibody against annexin 4 and 5
(dilution 1:50; Santa Cruz Biotechnology, Santa Cruz, CA, USA). Conditions used for each
antibody were as described by the manufacturer. Staining without the primary antibody was
performed as a negative control. The Envision system, HRP, anti-mouse or anti-rabbit was
used for the detection of the primary antibodies (Dako, Carpinteria, CA, USA) and tissue stain-
ing was visualised with diaminobenzidine (DAB) chromogen solution (Dako, Carpinteria, CA,
USA). Nuclei were counterstained with haematoxylin for 5 min. The sections were dehydrated
through a series of graded alcohols cleared in xylene and mounted in di-n-butyl phthalate in
xylene (DPX) mounting medium. Histochemistry to detect HPA binding utilised 10 μg/ml bio-
tinylated lectin in phosphate buffered saline (PBS) with 5% w/v bovine serum albumin (BSA)
applied to the slides for 1 h, washed in three changes of PBS with 0.01% v/v Tween-20 and
incubated with 5 μg/ml streptavidin-HRP for 30 min. The sections were washed again in
changes of PBS with 0.01% v/v Tween-20 and lectin binding was revealed by incubation with
1% w/v DAB and 0.3% v/v H2O2. The cells were counterstained and mounted as above.
Slides were evaluated under a light microscope and were scored by two independent indi-
viduals in a blinded manner. In cases where there was initial disagreement, a consensus was
obtained after discussion. P53 was recorded as positive when the tumour cell nuclei were
stained, irrespective of the percentage of positive cells. The overall immunoreactive score was
determined (for P53) according to the method used previously [6]. IRS is the cumulative value
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of the intensity of immunostaining (0 (-) for no staining; 1 (+) for weak staining; 2 (++) for
moderate staining and 3 (+++) for strong staining) and the percentage of positive tumour cells
<5% = 0; 20% = 1; 20–50% = 2; 50–80% = 3 and>80% = 4. For HPA and annexin 4, the same
criteria were used. First the percentage of cancer cells staining was assessed and this was then
added to the intensity score to give a final score of between 0 and 8. In order to determine the
optimum cut-off, the results from all the samples were analysed in terms of their staining score.
The score which gave the greatest discrimination between the patients who developed meta-
static disease and those who remained disease free (5-year survival data) was used as the cut-
off value.
DNA extraction
Samples of tumour tissue and normal tissue from each patient were used for DNA extraction.
Sections of 1 mm3 tissue were cut and crushed immediately in 200 μl of lysis buffer pH 7.5 con-
taining 10 mM Tris, 1 mM EDTA, 0.5% v/v SDS, 100 μg/ml proteinase K. Phenol extractions
were performed and the DNA was precipitated with ethanol at -20°C. The resulting precipitate
was dried at room temperature and re-suspended in sterile Tris-EDTA (TE) buffer at a concen-
tration of approximately 1 mg/ml. DNA concentration was determined using a GeneQuant
Pro spectrophotometer (GE Healthcare, Bucks, UK). The samples were stored at +4°C until
use.
DNA amplification
The amplification reaction of the DNA extracted from normal and tumour tissue were per-
formed using 1 μl DNA sample in a total reaction volume of 50 μl containing Promega Master
Mix (Ref. M7502) and primers generated by Dr. E. Jullian of Cochin Hospital. The amplifica-
tion reaction was carried out in two stages, with 12 pM of each primer. The first PCR reaction
(KRAS1) was performed with the following primers: KRN5 '(5'-TAAGGCCTGCTGAAAAT
GAC—3') and KRN3 '(5'-TGAAAATGGTCAGAGAAACC—3') with the following amplifica-
tion cycle: 95°C for 10 min, 55°C for 1 min, 72°C for 1 min, then 43 cycles of 95°C for 30 sec,
55°C for 30 sec, 72°C for 1 minute, and a final extension at 95°C for 30 sec, 55°C for 30 sec,
72°C for 10 min. The observation of a weak band of low intensity or of the lack of band, after
1.5% w/v agarose gel electrophoresis led to a second amplification reaction. This second PCR
reaction (KRAS2) was carried out using 2 to 10 μl of the first reaction KRAS1 and the following
primers: KRS5 '(5'—AACTTGTGGTAGTTGGAG -3 ') and KRS3' (5 '- GTTGGATCATAT
TCGTCC -3') with the following amplification cycle: 95°C for 12 min, 52°C for 1 min, 72°C for
1 min, then 43 cycles of 95°C for 30 sec, 52°C for 30 sec,72°C for 1 min and a final cycle at 95°C
for 30 sec, 52°C for 30 sec, 72°C for 10 min. The PCR products from the tumour tissue were
sequenced for and mutations in codons 12 and 13 of the KRAS gene were identified (Millegen,
France).
Sample preparation for protein analysis
Prior to the selection of samples for proteomic studies, 7 μm frozen sections were cut and the
presence of cancer cells was confirmed by staining with haematoxylin and eosin. Samples con-
taining>60% cancer cells and haemolysis free were selected. Four protein pools were prepared:
LN positive (n = 6) CRC (LN+), adjacent healthy tissue (AdLN+); LN negative (n = 5) CRC
(LN-) and corresponding healthy tissues (AdLN-). The clinical pathological features of the
samples are shown in S1 Table. Proteins were extracted from each sample by washing 50 mg of
tissue three times with chilled PBS, homogenising in lectin buffer: 0.05 M TBS, 1 mM CaCl2,
1 mMMgCl2, pH 7.6 using a hand held homogeniser for 5 min with intermittent cooling on
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ice. The homogenate was centrifuged at 15,000 x g to collect the supernatant. Protein quantifi-
cation was carried out using the Qubit system (Qiagen, U.K.). The protein yields ranged from
5% to 7% of the wet weight of the tissue. Each of the pools comprised 100 μg of each of the can-
cer / normal protein preparations of the appropriate samples.
SDS-PAGE andWestern blotting
Proteins were separated by 1-DE sodium dodecyl sulphate polyacrylamide gel electrophoresis
(SDS-PAGE) using a 12% gel at 120 V for 1.5 h [14] and stained with Colloidal Coomassie
Blue G-250 [15]. Samples separated by SDS-PAGE were transferred to nitrocellulose using a
wet blotting system for 1.5 h at 110 V in transfer buffer: 25 mM Tris, 192 mM glycine, 20% v/v
methanol, blocked with 2% w/v BSA in TBS-Tween 0.05% v/v overnight and incubated with
5 μg/ml biotinylated HPA for 2 h followed by 1 h incubation with 2 μg/ml streptavidin-HRP
and probed with the DAB/H2O2. For analysis of the CEA levels a murine anti-CEA monoclonal
antibody (sc-55547, Santa- Santa-Cruz, CA, USA) was used at 5 μg/ml anti-CEA antibody for
2 h, incubated with 2 μg/ml peroxidase-conjugated anti-mouse IgG for 1 h and visualised as
above. To verify the levels of annexin 4 and 5 protein samples were separated and blotted as
before and probed with murine monoclonal anti-annexin 4/5 antibodies (sc-46693/ sc-74438,
Santa-Cruz, CA, USA) at 5 μg/ml overnight followed by incubation with goat anti-mouse IgG
(1 μg/ml) and developed with the enhanced chemiluminescence (ECL) substrate. The signal
was captured onto X-ray film using an exposure time of 1 min.
Enrichment of HPA binding glycoproteins
HPA affinity chromatography was used to enrich and purify HPA binding glycoproteins from
the tissue extracts. This allowed qualitative alterations in glycosylation and quantitative
changes in protein levels to be assessed. In addition, this step removed high abundance pro-
teins. A 5 ml HPA affinity chromatography column was prepared by coupling 10 mg of HPA
to a HiTrap NHS-activated Sepharose column (GE Healthcare, Bucks, UK) according to the
manufacturer’s instructions. 2 mg of pooled protein sample was loaded onto the column and
eluted with 0.25 M GlcNAc freshly prepared in lectin buffer. Samples were dialysed overnight
against TBS and freeze dried. Lyophilised samples were reconstituted in 100 μl urea buffer: 7 M
urea, 2 M thiourea, 2% v/v ampholytes 4–7 (GE Healthcare, Bucks, UK), 4% w/v CHAPS and
1% w/v DTT. Protein quantification was carried out as before. The yield of affinity purified
protein ranged from 1% to 2% of the total protein pool.
Two dimensional electrophoresis (2-DE)
Affinity purified glycoproteins were separated by 2-DE. 50 μg of each pooled protein sample
was mixed with rehydration buffer: 6 M urea, 2M thiourea, 0.5% v/v CHAPS, 0.4% v/v DTT,
0.5% v/v ampholytes pH 4–7, to give a final volume of 120 μl. The mixture was loaded onto an
11 cm Immobiline pH gradient strip, pH 4-7L (GE Healthcare, Bucks, UK) according to the
method described by [16]. Isoelectric focusing was performed using a Multiphor II (GE Health-
care, Bucks, UK) 10,000 Vh (GE Healthcare, 2004). After focusing, the IPG strip was stored at
-80°C until separation by SDS-PAGE as described above. Three replicates of each of the affinity
purified glycoprotein pools were separated by 2-DE and visualised by staining with Colloidal
Coomassie Blue G-250 [15]. Gel images were captured using a GS-800 Densitometer (BioRad,
UK).
O-Linked Glycoproteins in Colorectal Cancer
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Analysis of 2-DE separations
The 2-DE separations were analysed to identify glycoproteins present in different levels in the
CRC specimens of patients with LN positive disease. Scanned image files were analysed using
the Progenesis PG240 SameSpots software (Nonlinear Dynamics, U.K.), relative protein quan-
tity in a given spot is inferred from the pixel intensity value and converted to a percentage of
the total intensity of all protein spots on the gel. Glycoproteins showing altered levels were
ranked according to the p-value (one way ANOVA) and the fold-change values.
Matrix assisted laser desorption ionisation mass spectrometry (MS)
analysis
Protein identification was carried out by commercial arrangement with Dr Kevin Bailey,
School of Biomedical Sciences, University of Nottingham. Protein spots were excised from the
2-DE separated gels; desalted using reversed phase C18ZipTips (Millipore, UK). 2 μl of desalted
peptide sample was spotted onto a single target well on a stainless steel matrix-assisted laser
desorption ionisation (MALDI) plate with 1 μl alpha cyano-4-hydroxycinnaminic acid con-
taining internal standard (adeno corticotrophic hormone, ACTH). The target was allowed to
air dry and analysed using in a MALDI-MS (MicroMass M@LDI, Waters Corp) operating res-
olution>10,000 full width at half maximum) in reflection mode. Spectra were acquired at 5 Hz
using a nitrogen laser (λ 337 nm) with 10 shots summed per spectra. Data was acquired by ran-
domly sampling from the target plate and the peptide peak list files were generated both manu-
ally and automatically. The backgrounds peaks from trypsin and keratin were excluded and the
peak lists were loaded into the MASCOT PMF (http://www.matrixscience.com/) database
search engine with parameters set as follows: peptide tolerance 0.2 Da; modifications during
the digestion process such as oxidized methionine and CAM were accounted for and missed
cleavages was set to 1.
Prediction of post-translational modifications (PTM)
Bioinformatic analysis was undertaken using the NetNGlyc; NetOGlyc; YinOYang; NetPhos
tools at http://www.cbs.dtu.dk/services to identify potential N-linked, O-GalNAc, O-GlcNAc
and O-phosphate modification sites on the HPA binding proteins identified above.
Statistical analysis
Comparisons between the 2 groups (lymph node positive/negative CRC) were made using the
Student’s independent samples t-test for continuous data and ANOVA for categorical vari-
ables. The Pearson coefficient was also used to determine if the levels of HPA or annexin
binding were associated with disease-free interval. Survival curves were plotted according to
the Kaplan-Meier method and compared using the log-rank test; for all the tests undertaken,
P values of<0.05 were taken as statistically significant. All statistical analyses were performed
using SPSS version 19 (SPSS Inc., Chicago, IL, USA, IBM Company).
Results and Discussion
Proteomic analysis ofO-linked glycoproteins in CRC
Pooled proteins from CRC tissues were fractionated using HPA affinity chromatography, sepa-
rated by 1-DE and 2-DE and identified using MS, in a proteomic approach aimed at character-
ising the O-linked glycans elevated in CRC metastatic to the lymph nodes (Fig 1 and S1 Fig).
Seven glycoproteins were identified using this approach (Table 1) including the cell membrane
O-Linked Glycoproteins in Colorectal Cancer
PLOS ONE | DOI:10.1371/journal.pone.0138345 October 23, 2015 6 / 14
proteins annexin 4, annexin 5 and the calcium activated chloride channel protein 1 (CLCA1).
Annexin 4 has previously been identified as an HPA binding glycoprotein in the colorectal can-
cer cell line HT29 [12]. Alongside the increased levels of O-linked glycosylation, increased lev-
els of CEA was also identified (S1 Fig) suggest that N-linked glycosylation also increase in
metastatic CRC cancer.
Fig 1. 2-DE analysis ofO-linked glycoproteins affinity purified using HPA. Proteins pooled from LN+ve CRC tissue specimens were affinity purified with
HPA and separated by isoelectric focussing on a pH 4–7 IPG strip and then by SDS-PAGE (12%) and visualised using colloidal Coomassie Blue. Inset:
annexin 4/5 as indicated in LN+ve compared with LN-ve CRC tissue specimen protein pools. The proteins identified in the MALDI-MS analysis are indicated.
doi:10.1371/journal.pone.0138345.g001
Table 1. Identification of the HPA binding proteins, affinity purified and separated by 2-DE, identified using MALDI-MS. The protein accession num-
ber, description, MASCOT score, sequence coverage, nominal mass and predicted pI are indicated. Fold change is the ratio between the mean normalised
volume of the spot separated by 2-DE from the LN+ve group and the LN-ve group.
Protein Accession
number
Protein description MASCOT
score
Sequence
coverage %
Nominal Mass
9kDa)
Predicted
pl
Fold
change
gi|119571135 GATA binding protein 56 23 11953 8.95 -3
gi|31615935 Fc fragment of IgA receptor 59 22 23642 7.12 3.5
gi|223468574 Vesicle associated membrate
protein
46 20 20336 9.39 -2.8
gi|119590003 Transcription factor 48 18 37679 5.17 2.5
gi|4585469 Calcium-activated chloride channel
protein 1
130 11 10081 5.97 2.5
gi|114577910 Annexin IV 99 25 31535 5.36 3.2
gi|157831404 Annexin V 120 25 35839 4.98 2.8
doi:10.1371/journal.pone.0138345.t001
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O-linked glycosylation, p53 and KRASmutation status
A histochemical approach was used with HPA as a marker of O-linked glycosylation status.
The majority of the samples were reactive with the lectin (n = 24, of total n = 27 cases) and
exhibited intense cell membrane staining with fewer cases showing granular cytoplasmic stain-
ing, perhaps representing the binding of the lectin to glycoconjugates in transit through the
Golgi apparatus (Fig 2). The light microscope does not provide sufficient resolution to allow
close interrogation of the intracellular organelles of the tissues that bound HPA. It is possible
that some of the glycoproteins identified in this study are, therefore, proteins in transit through
the secretory pathway, including the Golgi apparatus, however, much of the HPA binding
observed using immunohistochemistry was cell membrane associated. There was no relation-
ship between HPA staining intensity and patient age, sex, tumour grade or LN status but this
may reflect the relatively few samples in this initial analysis (data not shown). The anti-p53
antibody was strongly reactive in 13 of the 29 cases and weakly reactive in a further 7 cases
(Fig 2) and the O-linked glycosylation status did not correlate with the P53 staining. All of the
P53 positive cases (n = 15) bound HPA as well as some of the P53 negative cases (n = 8). The
KRASmutation status was assessed using a PCR based approach and 8 of the 25 evaluable spec-
imens exhibited mutated KRAS in either codon 12 or 13 (26% of the cases), this compared
favourably with the reported prevalence in CRC of between 30–40% [17]. Of 8 samples with
mutated KRAS, four were concurrently positive for HPA staining and all of these were P53 pos-
itive. Taken together these results are suggestive that O-linked glycosylation changes occur
early in the aetiology of CRC.
Fig 2. HPA lectin and P53 immunohistochemistry of CRC tissue specimens. Left: light microscopy images of colorectal tissue sections (5 μm) incubated
with HPA (10 μg/ml) and streptavidin-HRP (5 μg/ml) or incubated with the anti-P53 antibody (1:200) and biotinylated horse rabbit anti-mouse IgG (1:1000) as
indicated. The brown colouration indicates the peroxidase reaction with DAB/H2O2, the nuclei were counterstained with haematoxylin (blue). Magnification
X400. Right: Table showing results for HPA, P53 and KRAS analysis.
doi:10.1371/journal.pone.0138345.g002
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Validation of the results of the proteomic analysis
Annexin 4 and annexin 5 levels were examined using Western blotting, Fig 3. After normalisa-
tion to the β-actin levels, a significant increase in the level of annexin 4 (but not annexin 5) was
observed in the CRC tissue specimens that had metastasised to the lymph nodes at the time of
diagnosis (student t-test, P = 0.05). Similarly, Western blots were probed with HPA and an
increase in the HPA binding glycoproteins was observed in samples from lymph node positive
patients (data not shown). This is consistent with findings of other studies reporting an
increase in O-linked glycosylation in poor prognosis metastatic CRC cancer. To determine
whether annexin 4 and HPA binding correlated with poor prognosis CRC an additional series
of 35 CRC specimens with patient follow up data were assessed using immunohistochemistry.
When the percentage of cells staining (0–100%) and the aggregate staining score (scale 0–7)
were considered, both were significantly inversely correlated with patient survival, Fig 4. For
example, when the aggregate staining score for HPA was taken as5 the median survival was
13 months compared with 68 months for a cut off5 (Chi square test 9.065; P value = 0.0026);
for annexin 4: when a cut off for the aggregate staining score of5 was taken the median sur-
vival was 17 months; in contrast a score of5 was associated with a median survival of 59.6
months (Chi square test 11.45; P value = 0.0007). When the results for both annexin 4 and
Fig 3. Evaluation of annexin 4 and 5 levels in CRC tissue specimens. Left: 10 μg of pooled proteins were separated by SDS-PAGE using samples from
patients with LN positive CRC (LN+ve) and LN negative CRC (LN-ve) blotted to nitrocellulose and probed with either an annexin 4 or 5 antibody followed by
incubation with anti-mouse IgG and visualisation using DAB/H2O2. Upper panel: Annexin 4/5 levels relative to actin levels using densitometric analysis of
Western blot data, the P value refers to unpaired Student t-test result, NS = not significant. Lower panel: Western blot analysis of annexin 4/5 and
corresponding β-actin blot is shown for two individual patient samples, either LN+ve or LN-ve as indicated. Right: 4 μm sections of FFPE CRC probed with
anti-annexin 4 antibody. Binding was visualised using DAB/H2O2 (brown) the nuclei were counterstained with haematoxylin (blue), magnification X400.
doi:10.1371/journal.pone.0138345.g003
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HPA were combined these remained significantly inversely associated with survival after
CRC, Fig 4. For annexin 4: taking a cut off of60% of cells staining, the median survival
was 11 months compared with 58 months for60% cells staining (Chi square test 7.466;
P value = 0.0063);. For HPA:50% cell staining resulted in a median survival of 11.5 months;
but when50% cell staining was taken median survival was 60 months (Chi square test 11.74;
P value = 0.0006), data not shown. These findings illustrate that the binding of HPA and anti-
annexin 4 antibodies to tissue sections of CRC are indicators of poor prognosis. Both the O-
linked glycosylation–as measured by HPA staining–and the levels of annexin 4 are markers of
poor prognosis CRC. The complexity of the proteome renders tumour marker discovery work
challenging; nevertheless, there is a need for the identification of biomarkers and new targets
for the treatment of CRC. Of the many post translational modifications to occur on proteins,
glycosylation is the most abundant and diverse [18] and aberrations in protein glycosylation
reported in cancer [19] offer potential for identification of cancer-specific changes. Carbohy-
drate binding proteins, lectins, have previously been described for the up-front capture of can-
cer-associated glycoproteins [20, 21]. There has been considerable interest in the glycoproteins
recognised by the lectin HPA as the involvement of HPA binding epitopes in the metastatic
process has been established using cancer cell lines derived from human tumour tissues [22].
Integrin α5 and α6 and annexin 2 and 4 have previously been identified as the main HPA bind-
ing partners in the metastatic CRC cell line HT29 [12]. In this study proteins from CRC tissue
samples were pre-fractionated using HPA affinity chromatography thereby allowing low abun-
dance proteins to be isolated and identified. Differences in the HPA binding glycoproteins in
specimens that had metastasised to the lymph nodes at the time of diagnosis were apparent
when the glycoproteins were separated by 1-DE and blotted to nitrocellulose—indicating an
overall increase in O-linked glycosylation; likely to be associated with Tn and sialyl-Tn antigen
expression in cancer [23]. When HPA was used to probe Western blots of the cancer protein
preparations, the number of bands and their intensity varied compared with when the proteins
had been pre-fractionated by lectin affinity chromatography (S1 Fig). This may reflect subtle
differences in binding when HPA was covalently immobilised to an affinity matrix compared
to when the lectin was in free solution. The identification of the HPA binding glycoproteins of
CRC was a significant aim of this work, these were compared to the levels of CEA from the
same tissue specimens and confirmed to be independent of the CEA levels (S1 Fig). Whilst the
Fig 4. Kaplan Meier survival curves.Upper: The scores for HPA or anti-annexin 4 antibody staining as indicated. Lower: Combined scores for HPA and
anti-annexin 4 staining.
doi:10.1371/journal.pone.0138345.g004
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study of mucins was beyond the scope of this current work, clearly the levels of MUC1 and
MUC2 and their HPA binding properties is a matter of some interest. Similarly, the intracellu-
lar localisation of the HPA binding proteins is of interest. It is not technically feasible to frac-
tionate cellular organelles when frozen cancer tissue samples are used as the starting material
and so we were unable to determine if glycoproteins from the Golgi apparatus were purified
using the affinity chromatography step. The primary aim was to identify proteins that bind the
lectin HPA and that are altered in metastatic and non-metastatic CRC. As the tissue-staining
using HPA showed both intracellular and intense membrane staining, we hypothesise that the
HPA binding glycoproteins identified in this study are likely to be derived from the cell mem-
brane, the cytosol and potentially, from the Golgi apparatus. Proteomic analysis of affinity
purified HPA binding proteins revealed seven glycoproteins including annexin 4 and 5 and
CLCA1 that were increased in the preparations from the metastatic cancer tissues. Annexin 4
has already been shown in a separate study to be recognised by HPA in the CRC cell line HT29
[12]. All three of these proteins have previously been described in relation to CRC but the pro-
teins have not previously been identified through pre-enrichment via O-linked glycan moeities.
Annexins are a family of calcium-regulated phospholipid and carbohydrate binding proteins
with diverse intra- and extracellular roles in range of cellular processes including signalling, ion
transport, cell division and apoptosis [24]. Alterations in the levels of annexins have been asso-
ciated with tumourigenesis in several types of tumours [25] and increased levels of annexin 4
and 5 have previously been reported in primary CRC compared with the normal colon tissue
[12, 26–28]. Annexin 4 was found to be up-regulated in renal carcinoma patient tissue samples
compared to adjacent healthy tissues [29]. Several other members of the annexin superfamily,
specifically annexin 1, 2, 3 and 7 are present in elevated levels in CRC [, 27,30,31]. Increased
levels of annexin 4 have been linked to a loss of cell-to-cell adhesion and increased tumour cell
dissemination of the human breast cancer cell line MCF7 [29] supporting the observations
here that increased levels of annexin 4 are associated with an aggressive metastatic phenotype.
Annexin 5 levels have been reported to be increased in liver metastasis of CRC [32]. In this
study annexin 4 was identified through lectin (HPA) affinity chromatography which captured
the glycoprotein through its glycan (mainly Tn-antigen) moieties. Therefore, whilst the protein
levels of annexin 4 have previously been shown to be altered in CRC, this is, to our knowledge,
the first report in which annexin 4 glycosylation has been recognised as being altered in CRC
tissue samples and levels correlated with poor prognosis CRC. The importance of cell mem-
brane ion channels for the development of cancer has been well established. CLCA1 and
CLCA2 were originally thought to form Ca+2 activated chloride channels, however evidence is
accumulating that these are accessory proteins, found in association with Ca2+ channels. The
role of CLCA1/2 in cancer remains unclear: CLCA1/2 have been reported to be down-regulated
in CRC suggesting a tumour suppressive role [33]. In contrast, conjugation of CLCA2 to β4
integrin has been shown to mediate cancer cell metastasis [34]. A hypothesis to explain the
increased levels of the CLCA1 protein detected in this study is that it might act as an adhesion
partner to β4 integrin in CRC, as β4 integrin has previously been shown to bind the lectin
HPA, however, further work is required to explore this idea more fully. Alongside the GalNAc
binding properties of HPA [5,6] the lectin also binds O-GlcNAc containing glycoproteins [13].
O-GlcNAcylation acts as an alternative signalling pathway to phosphorylation [35] and many
oncogene and tumour suppressor gene products harbour this post-translational modification
[36], for example, O-GlcNAcylation of p53 has been shown to regulate the protein activity and
stability by blocking ubiquitin-dependent proteolysis [37]. It is notable that a significant
increase in the O-GlcNAcylation in CRC tissues has been reported when compared to
healthy tissues [38]. Bioinformatic analysis was undertaken by inputting the amino acid
sequences for of the proteins identified in this study into the YinOYang and NetPhosp tools at
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www.cbs.dtu.dk. The results indicated that all of the proteins harbour potential O-GlcNAcyla-
tion and phosphorylation sites (S2 Fig).Elevated levels of CEA have been proposed as a predic-
tor of CRC liver metastasis [39, 40]. In the current study a positive correlation was observed
between CEA and annexin A4/A5 levels from the pooled protein samples, however a detailed
investigation using individual samples would be needed to explore any associations further.
This study has shown that HPA binds to CRC proteins of the same relative molecular mass as
CEA but HPA also recognised other lower molecular weight entities described above. Notably,
HPA binding epitopes were present in the CRC samples which were negative for mutated
KRAS and P53 supporting the hypothesis that changes in O-linked glycosylation is an event
that occurs early in the aetiology of CRC. Future investigations of microsatellite instability
would help to elucidate whether the O-linked glycosylation changes observed in CRC arise
from chromosomal instability, ineffective DNAmis-match repair mechanisms or potentially a
combination of both.
Conclusion
This study has identified annexin 4 as a major carrier of O-linked glycans in lymph node posi-
tive CRC tissue samples. The levels and intensity of staining of tissue sections with anti-
annexin 4 antibodies and with HPA was associated with significantly poorer survival after
CRC. Further work will seek to map the glycans of annexin 4 and to explore the function of
this protein in metastatic CRC. In order to reveal useful biomarkers for metastatic CRC a
larger, more diverse, CRC patient population will be investigated in future studies.
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